The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Subscribe To Our Newsletter & Stay Updated
